Genkyotex’s setanaxib granted Orphan Drug Designation by the European Commission for the treatment of PBC
Genkyotex announces the closing of the acquisition by Calliditas Therapeutics of a controlling interest in Genkyotex
Genkyotex provides business update and reports cash position at September 30, 2020
Genkyotex’s setanaxib granted Orphan Drug Designation by the US FDA for the treatment of PBC
Genkyotex announces first-half 2020 results and business update
Genkyotex announces the enrollment of the 1st patient in the Phase 2 trial of setanaxib in idiopathic pulmonary fibrosis (IPF)
Genkyotex announces agreement for Calliditas Therapeutics to acquire controlling interest in Genkyotex SA
Genkyotex provides business update and reports cash position at June 30, 2020
Genkyotex announces the dosing of the first subjects in its Phase 1 study with high-dose setanaxib
Genkyotex provides new clinical data from the PBC Phase 2 trial providing further evidence of the anti-fibrotic activity of setanaxib
Genkyotex receives approval from the ANSM to initiate a Phase 1 clinical study with high-dose setanaxib
Genkyotex provides business update and reports cash position at March 31, 2020
Genkyotex’s setanaxib significantly improves immunotherapy including checkpoint inhibitors in multiple preclinical cancer models
Genkyotex announces 2019 annual financial results and provides corporate update
Genkyotex raises €4.9 million in its rights issue
Genkyotex announces its financial calendar for 2020
Genkyotex launches a rights issue for a maximum amount of €6.13 million
Genkyotex provides business update and reports gross cash position at December 31, 2019
Half-yearly report on Genkyotex’s liquidity contract with Kepler Cheuvreux
Ask us your questions
Suscribe to Newsletter
